Although Fribbens et al. (23) showed encouraging activity of both fulvestrant and palbociclib against ESR1-mutant cancers, it is not known how palbociclib will affect the emergence of ESR1 mutations or whether fulvestrant plus palbociclib will have the same benefit in patients with prior palbociclib exposure (47). The gene discussed is ESR1; the disease is cancer.